Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VVP808 versus placebo in type 2 diabetes mellitus
ACTRN12609000634279Phase 2Recruiting
- Sponsor
- Verva Pharmaceuticals
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing VVP808 with Placebo (2 arms). Primary endpoints: Safety and tolerability based on incidence of acidosis using venous blood gas parameters and Change in glycated hemoglobin. Started Dec 2009; status: recruiting.
02
Drugs
methazolamide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12609000634279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000634279.